Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. - Wikidata - wikimedia - TriplyDB

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

http://www.wikidata.org/entity/Q34099171

about

Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study Association between white blood cell count and non-alcoholic fatty liver disease in urban Han Chinese: a prospective cohort study Research advances in the relationship between nonalcoholic fatty liver disease and atherosclerosis Comorbidities and Metabolic Derangement of NAFLD Omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease Management of dyslipidemia as a cardiovascular risk factor in individuals with nonalcoholic fatty liver disease Nonalcoholic fatty liver disease: Noninvasive methods of diagnosing hepatic steatosis Cardiovascular dysfunction in patients with liver cirrhosis Nonalcoholic fatty liver disease and vascular disease: state-of-the-art.Nonalcoholic fatty liver disease - A multisystem disease?Fatty liver is associated with an increased risk of diabetes and cardiovascular disease - Evidence from three different disease models: NAFLD, HCV and HIV Cardiovascular disorders in the context of non-alcoholic Fatty liver disease: a literature review Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis γ-Glutamyltransferase, but not markers of hepatic fibrosis, is associated with cardiovascular disease in older people with type 2 diabetes mellitus: the Edinburgh Type 2 Diabetes Study Nonalcoholic fatty liver disease: updates in noninvasive diagnosis and correlation with cardiovascular disease.Non-invasive determination of hepatic steatosis by acoustic structure quantification from ultrasound echo amplitude.Standardized ultrasound hepatic/renal ratio and hepatic attenuation rate to quantify liver fat content: an improvement method Nonalcoholic Fatty liver disease, diabetes mellitus and cardiovascular disease: newer data.Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.Nonoverweight nonalcoholic fatty liver disease and incident cardiovascular disease: A post hoc analysis of a cohort study Non-alcoholic fatty liver disease and cardiovascular risk.Nonalcoholic fatty liver disease and serum lipoproteins: the Multi-Ethnic Study of Atherosclerosis.Peroxisome proliferator-activated receptor α activation induces hepatic steatosis, suggesting an adverse effect NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk.Clinical importance of epicardial adipose tissue.Reduced hepatic eNOS phosphorylation is associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise in hyperphagic OLETF rats Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.Physical activity and risk of fatty liver in people with different levels of alcohol consumption: a prospective cohort study.Links between ectopic fat and vascular disease in humans Is there an effective therapy available for non-alcoholic fatty liver disease?Association between serum γ-glutamyltranspeptidase and atherosclerosis: a population-based cross-sectional study.A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease.VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation.Simple non-invasive biomarkers of advanced fibrosis in the evaluation of non-alcoholic fatty liver disease.Non-alcoholic fatty liver disease: An early mediator predicting metabolic syndrome in obese children?Silymarin in non alcoholic fatty liver disease.Independent and supra-additive effects of alcohol consumption, cigarette smoking, and metabolic syndrome on the elevation of serum liver enzyme levels Risk stratification of non-contrast CT beyond the coronary calcium scan.Circulating pancreatic polypeptide concentrations predict visceral and liver fat content.

P2860

Q24596256-C494FD07-58AC-4CFF-BA9B-F866A4649D25 Q24658538-20AA4E66-6C43-4D93-9CC1-B1D111B6C12A Q26775340-C4CBC56E-F046-4901-821C-8B2CE58A37EC Q26777147-E934680C-767A-43A1-A62C-2E040FE1F3A6 Q26825517-107EB328-78AB-420C-B2B7-06C89D25CB28 Q26827665-7B0BF98D-A071-4CDC-A5FC-048BF3EE5BFF Q26858875-06B5CF32-4821-42F4-936C-062AF33B502F Q27010592-7AF928FD-68E9-40CC-AC54-F36A45B4F3B2 Q27692035-22D02494-EDA7-47A5-A0C6-C20594A5C57A Q28079077-02BF0738-502B-4C9A-AFB6-8D5B2CE02295 Q28079826-D042DE57-2212-43A0-94D5-EDE0FAE127A2 Q28081066-92B34A05-11B5-4C88-8767-66684992C338 Q28084150-D02BF2D7-69E1-4458-A49D-538533C959CE Q28648219-14EB88DA-1B16-44FD-A6C8-E2EEBFECA3D9 Q30435948-6E84D1AB-C1FE-41D4-AC92-902A5590B2CD Q30464853-9A2A4D56-EB8D-4760-941A-BF971111FFC9 Q30504580-75B1F4DF-5CE6-4089-B0D1-1AA5A6079178 Q30622511-6F229808-D2DC-4F36-8B9D-552A95A0CBBA Q33640536-EE9D0293-6074-498D-B356-0F1FD99577BA Q33644131-FD339A22-B3D7-43D8-BB22-BCD5CEA454BE Q33706265-D09738C9-DDA0-42F2-92B1-6628C0B8BE10 Q33724815-616E1309-F68C-49A4-AF7F-B3DD5BA9D202 Q33753420-26FE9C4F-DA7F-40A9-B532-DB19429E6832 Q33844463-9169CEB4-1C14-4EA5-878F-527EF42A6D71 Q33897351-430CAB56-0E03-4DD2-AC19-6D3FF97C75B4 Q33900501-B52F9365-ADB4-40B5-91DC-D1ECAC24E0A3 Q33932951-F07EDA88-C96F-4D96-A8DC-3E64570872FC Q33937311-7377F8F5-B218-4984-8633-24C6E4F2F32F Q34024582-62447EF1-4C87-406D-B0E7-F29BBC2FAD07 Q34076155-4339F121-8109-4A34-AA00-E00F623DDAC1 Q34076451-76C05B3B-280B-432B-A2B4-7A610C266786 Q34296980-5DB2DDB9-B319-4A85-ADD9-20EE8452538E Q34301287-A5B850AB-9D8C-40AC-9656-33A99295F396 Q34428997-FC2A0F9E-9700-48F3-8A0B-0F865A0DFAED Q34447506-763A17BE-6F46-467D-9F97-77191A15E203 Q34591166-1CBAE22A-DD45-4740-8314-F920FD1AC25A Q34650071-814CC377-B2D6-42DF-8983-2230E8B5BE53 Q34718164-4073FA31-9DE1-4C47-86E5-F8E87E4D5249 Q34778776-B414CD21-FC77-4C91-9288-1332D0602A11 Q35096854-1A850070-C71A-401C-B4D5-4DC4BF530610

P2860

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

http://www.wikidata.org/entity/Q34099171

description

2007 nî lūn-bûn

@nan

2007 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2007 թվականի մարտին հրատարակված գիտական հոդված

@hy

2007年の論文

@ja

2007年論文

@yue

2007年論文

@zh-hant

2007年論文

@zh-hk

2007年論文

@zh-mo

2007年論文

@zh-tw

2007年论文

@wuu

name

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@ast

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@en

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@nl

type

label

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@ast

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@en

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@nl

prefLabel

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@ast

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@en

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

@nl

P1433

Q34099171-7EE5305F-0DB9-40EE-A2E4-EBC0F20CEE1D

P1476

Q34099171-3427958E-0282-4A79-8192-F76CC2A87460

P2093

Q34099171-319C086E-8877-4B1A-A532-81B0D858B2A7

Q34099171-44D7ACA5-2949-4C59-B8C9-4823C413EA84

Q34099171-47B53DE9-2726-42C2-8327-5676A16991F4

Q34099171-525D4FAB-095E-450B-B639-2DC5836E9EF4

Q34099171-69523AD9-E4EA-46E9-AF68-109FC75CAAB9

Q34099171-6F78CE80-F350-4321-8B00-86E1DA990AA8

Q34099171-772DFC13-30CA-4BF8-8DF1-51DA3193D719

Q34099171-917C5AF5-6DEC-44AB-ACA4-AAAA3172C60B

Q34099171-91B4127E-9714-48C2-BF36-DCD4202EAEDA

Q34099171-A7961A29-8B3F-426A-A8C6-C998279143FC

P2860

Q34099171-0809C39C-F2AA-4F08-86E9-4B4EFA4327DB

Q34099171-0CCBD2E2-C2D6-4FF2-B727-D9F74C0A3000

Q34099171-0F24E3F3-9494-4C5B-B290-4872D8E0A06E

Q34099171-180EF42E-B72D-4522-834D-C693F6312615

Q34099171-2EF241BC-F8A0-4585-9736-1871A0A0EC8C

Q34099171-339E6425-F4D3-4C0E-9C0B-1D0D56A5D76E

Q34099171-431CFFDA-597E-4D3B-BE73-4CB67E52CED1

Q34099171-58073C42-A1F8-4613-9C0D-B55163B7DD80

Q34099171-584E05C3-D486-41B9-BDEF-2834E05C15B7

Q34099171-65C7BDF4-B014-4AE9-A41E-F49C788C0344

P304

Q34099171-12AF681E-D9D0-450F-8440-FCE5438519DE

P31

Q34099171-05E116CF-34F4-4CA5-BF6E-B5DE3AACE6D1

P356

Q34099171-7C72C9C2-D68B-4A43-AAFA-04842D5E2D61

P407

Q34099171-7847823C-5B1C-4B43-B515-D6973CC0A169

P433

Q34099171-A97343B2-C11E-4825-A3D1-5E4B4C1F7A7C

P478

Q34099171-0020AAEE-F87D-48C7-9F94-DB38CB215824

P50

Q34099171-5521D222-6EC8-487E-ABE0-DE948EC2EA01

P577

Q34099171-9DECCE1A-66B0-4A84-9181-B5C04DA8EFDA

P698

Q34099171-5EC6B2C6-1BEE-4FB8-9489-7445557F0FDD

P921

Q34099171-550FD256-EA77-4D39-9485-6916D7BB97A9

P932

Q34099171-C64FF150-4751-499A-8A72-2DFDB0280BA5

P356

WJG.V13.I10.1579

P1433

World Journal of Gastroenterology

P1476

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease

@en

P2093

Atsushi Suetsugu

http://www.w3.org/2001/XMLSchema#string

Chisato Nagata

http://www.w3.org/2001/XMLSchema#string

Hiroshi Sarui

http://www.w3.org/2001/XMLSchema#string

Jun Takeda

http://www.w3.org/2001/XMLSchema#string

Junichi Okuda

http://www.w3.org/2001/XMLSchema#string

Kazunori Ida

http://www.w3.org/2001/XMLSchema#string

Masahide Hamaguchi

http://www.w3.org/2001/XMLSchema#string

Naohisa Yoshida

http://www.w3.org/2001/XMLSchema#string

Noriyuki Takeda

http://www.w3.org/2001/XMLSchema#string

Takahiro Kato

http://www.w3.org/2001/XMLSchema#string

P2860

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

The Metabolic Syndrome is an independent predictor of cardiovascular disease in Type 2 diabetic subjects. Prospective data from the Verona Diabetes Complications Study.

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease.

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background.

Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference.

Increased prevalence of fatty liver in arterial hypertensive patients with normal liver enzymes: role of insulin resistance

Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock?

Hepatic steatosis and vascular disease.

P304

1579-1584

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3748/WJG.V13.I10.1579

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Yutaka Kawahito

P577

2007-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

17461452

http://www.w3.org/2001/XMLSchema#string

P921

cardiovascular disease

P932

4146902

http://www.w3.org/2001/XMLSchema#string